伊立替康治疗胃癌的研究进展

被引：1

作者：

王丹玲 ^{[1
,2
]}

陈锦飞 ^{[1
,2
]}

机构：

[1] 东南大学医学院

[2] 南京市第一医院肿瘤科

来源：

中国肿瘤外科杂志 | 2010年 / 2卷 / 05期

关键词：

晚期胃癌; 转移性胃癌伊立替康联合方案; 临床试验;

D O I：

暂无

中图分类号：

R735.2 [胃肿瘤];

学科分类号：

100112 [医学生物化学与分子生物学];

摘要：

晚期进展或复发转移性胃癌目前尚无标准的治疗方案,大部分胃癌的化疗方案疗效不佳且毒副反应较大,很多患者不能耐受,从而导致其临床运用的局限性。文献报道伊立替康无论是单药还是联合其他化疗药物治疗晚期转移性胃癌都有很好的治疗效果,尤其是目前被广泛采用的FOLFIRI方案,不仅可作为晚期进展或复发转移性胃癌的一线化疗方案,也可作为其他一线化疗方案治疗失败后的二线方案,且耐受性较好。口服的氟尿嘧啶的前体药物卡培他滨,分子靶向药物西妥昔单抗、曲妥珠单抗和贝伐单抗等,以及多靶点抗代谢药物培美曲塞等的层出不穷,为今后伊立替康联合用药提供了很好的研究方向。本文就伊立替康单药及联合其他化疗药物治疗晚期进展或复发转移性胃癌进行综述。

引用

页码：307 / 310

页数：4

共 10 条

[1]

Phase Ⅱ study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer.[J].Hiroshi Imamura;Masataka Ikeda;Hiroshi Furukawa;Toshimasa Tsujinaka;Kazumasa Fujitani;Kenji Kobayashi;Hiroyuki Narahara;Michio Kato;Haruhiko Imamoto;Arimichi Takabayashi;Hideaki Tsukuma;.World Journal of Gastroenterology.2006, 40

[2]

Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer [J].

Cao, Weiguo ;

Yang, Weiping ;

Lou, Guying ;

Jiang, Jinsong ;

Geng, Mei ;

Xi, Wenqi ;

Li, Hao ;

Ma, Tao ;

Jin, Yening .

ANTI-CANCER DRUGS, 2009, 20 (04) :287-293

[3]

Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group [J].

Comella, Pasquale ;

Lorusso, Vito ;

Maiorino, Luigi ;

Casaretti, Rossana ;

Cannone, Michele ;

Massidda, Bruno ;

Putzu, Carlo ;

Leo, Silvana ;

Roselli, Mario ;

Mancarella, Sergio ;

Palmeri, Sergio ;

Greco, Ettore ;

Vessia, Giacomo ;

Sandomenico, Claudia ;

Franco, Luca .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (05) :893-899

[4]

A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma [J].

Brell, Joanna M. ;

Krishnamurthi, Smitha S. ;

Javle, Milind ;

Saltzman, Joel ;

Wollner, Ira ;

Pelley, Robert ;

Dowlati, Afshin ;

Kantharaj, Belagodu N. ;

Schluchter, Mark D. ;

Rath, Linda ;

Ivy, S. Percy ;

Remick, Scot C. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (05) :851-857

[5]

Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin [J].

Kim, Sun Young ;

Kim, Hwang Phill ;

Kim, Yu Jung ;

Oh, Do Youn ;

Im, Seock-Ah ;

Lee, Dongsoon ;

Jong, Hyun-Soon ;

Kim, Tae-You ;

Bang, Yung-Jue .

INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 32 (01) :89-95

[6]

Phase I clinical and pharmacokinetic study of oxaliplatin; irinotecan and capecitabine.[J].Smitha S. Krishnamurthi;Joanna M. Brell;Charles L. Hoppel;Merrill J. Egorin;Karen C. Weaver;Xiaolin Li;Stephen T. Ingalls;Eleanor G. Zuhowski;Mark D. Schluchter;Afshin Dowlati;Matthew M. Cooney;Joseph Gibbons;Beth A. Overmoyer;S. Percy Ivy;Scot C. Remick.Cancer Chemotherapy and Pharmacology.2008, 3

[7]

A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer [J].

Sym, Sun Jin ;

Chang, Heung Moon ;

Kang, Hye Jin ;

Lee, Sung Sook ;

Ryu, Min-Hee ;

Lee, Jae-Lyun ;

Kim, Tae-Won ;

Yook, Jeong Hwan ;

Oh, Sung Tae ;

Kim, Byung Sik ;

Kang, Yoon-Koo .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) :1-8

[8]

A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer [J].

Farhat, Fadi Sami .

MEDICAL ONCOLOGY, 2007, 24 (02) :137-146

[9]

Irinotecan plus cisplatin combination against metastatic gastric cancer.[J].Mustafa Altinbas;Ozlem Er;Metin Ozkan;Yusuf Solak;H. Senol Coskun;Can Kucuk;Sebnem Gursoy.Medical Oncology.2005, 2

[10]

Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer [J].

García, I ;

Vizoso, F ;

Martín, A ;

Sanz, L ;

Abdel-Lah, O ;

Raigoso, P ;

García-Muñiz, JL .

ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (03) :234-241

← 1 →